Introduction
Dr. Michael J. Keating’s development of fludarabine continues to play a major role in clinical research as this drug is now established as the most important single agent in CLL and a major component of treatment for patients with low-grade lymphoma, acute myelogenous leukemia, myelodysplastic syndrome and those undergoing marrow stem-cell transplantation. At present, he is working on developing new potentially curative therapies for CLL and rational combinations of new agents for the treatment of leukemias and other hematologic malignancies.
Dr. Keating is a Professor of Medicine and Internist in Hematology at the University of Texas MD Anderson Cancer Center. He has been a member of the faculty of the MD Anderson Cancer Center (MDA) since 1977 and works as a physician in the Department of Leukemia.